New hope for heart patients: drug may prevent dangerous stomach bleeding
NCT ID NCT07479056
First seen Mar 22, 2026 · Last updated May 14, 2026 · Updated 10 times
Summary
This study tests whether fexuprazan, a new stomach acid reducer, can prevent upper gastrointestinal bleeding in 400 heart patients at high risk for bleeding who are taking two blood thinners after coronary stent placement. Participants receive either fexuprazan or the standard drug lansoprazole daily for 6 months, and the study tracks stomach-related complications like bleeding, ulcers, and severe pain. The goal is to see if fexuprazan offers better protection than the current standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE (CAD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Catholic University of Korea, Eunpyeong St. Mary's Hospital
RECRUITINGSeoul, Eunpyeong-gu, 03312, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.